Genmab
GMAB
256 hedge funds and large institutions have $1.94B invested in Genmab in 2025 Q3 according to their latest regulatory filings, with 68 funds opening new positions, 99 increasing their positions, 63 reducing their positions, and 28 closing their positions.
336% more call options, than puts
Call options by funds: $2.43M | Put options by funds: $558K
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
143% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 28
57% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 63
17% more funds holding
Funds holding: 219 → 256 (+37)
0.3% less ownership
Funds ownership: 10.34% → 10.04% (-0.3%)
12% less capital inflows, than outflows
Capital inflows: $293M | Capital outflows: $331M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Paradigm Biocapital Advisors
New York
|
+$93M |
| 2 |
Orbis Allan Gray
Hamilton,
Bermuda
|
+$76.9M |
| 3 |
Harding Loevner
Bridgewater,
New Jersey
|
+$13.7M |
| 4 |
Deep Track Capital
Greenwich,
Connecticut
|
+$11.7M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$85.7M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$33.5M |
| 3 |
Morgan Stanley
New York
|
-$24.9M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$19.9M |
| 5 |
JP Morgan Chase
New York
|
-$19.9M |
GMAB Hedge Fund Activity: Q3 2025 in Review
256 of the 7,660 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q3 2025, worth a combined $1.94B — up 47% from $1.33B a quarter earlier.
Buyers outnumbered sellers: 68 funds opened new GMAB positions and 28 closed out — a net gain of 40 holders — while 99 added to existing stakes and 63 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $93M. The largest seller was Citadel Advisors, cutting an estimated $85.7M.
- 256 institutional investors held Genmab (GMAB) as of Q3 2025, up from 219 in Q2 2025.
- Funds reported $1.94B of Genmab stock for Q3 2025, up 47% quarter-over-quarter.
- 68 funds opened new Genmab positions in Q3 2025 and 28 closed out, a net change of +40 holders.
- The largest Genmab buyer in Q3 2025 was Paradigm Biocapital Advisors, an estimated $93M added.
- The largest Genmab seller in Q3 2025 was Citadel Advisors, an estimated $85.7M sold.
Based on aggregated 13F filings for Q3 2025.